These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
377 related articles for article (PubMed ID: 15190196)
21. Real-world patient data on immunity and COVID-19 status of patients with MPS, Gaucher, and Pompe diseases from Turkey. Kilavuz S; Kor D; Bulut FD; Serbes M; Karagoz D; Altıntas DU; Bisgin A; Seydaoğlu G; Mungan HNO Arch Pediatr; 2022 Aug; 29(6):415-423. PubMed ID: 35705384 [TBL] [Abstract][Full Text] [Related]
22. FDA orphan drug designations for lysosomal storage disorders - a cross-sectional analysis. Garbade SF; Zielonka M; Mechler K; Kölker S; Hoffmann GF; Staufner C; Mengel E; Ries M PLoS One; 2020; 15(4):e0230898. PubMed ID: 32267884 [TBL] [Abstract][Full Text] [Related]
23. Nanotechnology-based approaches for treating lysosomal storage disorders, a focus on Fabry disease. Abasolo I; Seras-Franzoso J; Moltó-Abad M; Díaz-Riascos V; Corchero JL; Pintos-Morell G; Schwartz S Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 May; 13(3):e1684. PubMed ID: 33314628 [TBL] [Abstract][Full Text] [Related]
24. Enzyme Replacement Therapy: A Review and Its Role in Treating Lysosomal Storage Diseases. Li M Pediatr Ann; 2018 May; 47(5):e191-e197. PubMed ID: 29750286 [TBL] [Abstract][Full Text] [Related]
25. Therapeutic approaches for lysosomal storage diseases: a patent update. Urbanelli L; Sagini K; Polidoro M; Brozzi A; Magini A; Emiliani C Recent Pat CNS Drug Discov; 2013 Aug; 8(2):91-109. PubMed ID: 23713988 [TBL] [Abstract][Full Text] [Related]
27. Pulmonary involvement in selected lysosomal storage diseases and the impact of enzyme replacement therapy: A state-of-the art review. Jezela-Stanek A; Chorostowska-Wynimko J; Tylki-Szymańska A Clin Respir J; 2020 May; 14(5):422-429. PubMed ID: 31912638 [TBL] [Abstract][Full Text] [Related]
28. A chaperone-mediated approach to enzyme enhancement as a therapeutic option for the lysosomal storage disorders. Pastores GM; Sathe S Drugs R D; 2006; 7(6):339-48. PubMed ID: 17073517 [TBL] [Abstract][Full Text] [Related]
29. A charitable access program for patients with lysosomal storage disorders in underserved communities worldwide. Mehta A; Ramaswami U; Muenzer J; Giugliani R; Ullrich K; Collin-Histed T; Panahloo Z; Wellhoefer H; Frader J Orphanet J Rare Dis; 2021 Jan; 16(1):8. PubMed ID: 33407729 [TBL] [Abstract][Full Text] [Related]
34. Neurological manifestations of lysosomal disorders and emerging therapies targeting the CNS. Giugliani R; Vairo F; Kubaski F; Poswar F; Riegel M; Baldo G; Saute JA Lancet Child Adolesc Health; 2018 Jan; 2(1):56-68. PubMed ID: 30169196 [TBL] [Abstract][Full Text] [Related]
35. Receiving enzyme replacement therapy for a lysosomal storage disorder: a preliminary exploration of the experiences of young patients and their families. Freedman R; Sahhar M; Curnow L; Lee J; Peters H J Genet Couns; 2013 Aug; 22(4):517-32. PubMed ID: 23536258 [TBL] [Abstract][Full Text] [Related]
37. Patients' view on gene therapy development for lysosomal storage disorders: a qualitative study. Eskes ECB; Beishuizen CRL; Corazolla EM; van Middelaar T; Brands MMMG; Dekker H; van de Mheen E; Langeveld M; Hollak CEM; Sjouke B Orphanet J Rare Dis; 2022 Oct; 17(1):383. PubMed ID: 36271424 [TBL] [Abstract][Full Text] [Related]
38. Biotherapeutic target or sink: analysis of the macrophage mannose receptor tissue distribution in murine models of lysosomal storage diseases. Zhang XS; Brondyk W; Lydon JT; Thurberg BL; Piepenhagen PA J Inherit Metab Dis; 2011 Jun; 34(3):795-809. PubMed ID: 21416197 [TBL] [Abstract][Full Text] [Related]
39. The NCS-LSD cohort study: a description of the methods and analyses used to assess the long-term effectiveness of enzyme replacement therapy and substrate reduction therapy in patients with lysosomal storage disorders. Henley WE; Anderson LJ; Wyatt KM; Nikolaou V; Anderson R; Logan S J Inherit Metab Dis; 2014 Nov; 37(6):939-44. PubMed ID: 24519353 [TBL] [Abstract][Full Text] [Related]